Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of ($0.80), $0.03 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $71.1 million versus the consensus estimate of $53.65 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.